GLP-1 therapies are expected to reduce prevalence by less than 5%, showing obesity is only one of several contributing factors. “This study reaffirms that the number of people with OSA is expected to dramatically increase,” says study co-author Carlos Nunez, MD, Resmed chief medical officer, in a release. The impact of GLP-1 therapies on future OSA prevalence is anticipated to be limited, with reductions estimated at under 5%: Even with advances in emerging drugs, such as GLP-1s, the overall number of people affected by OSA is expected to continue growing. GLP-1 use is estimated to reduce relative OSA prevalence by only 4% by 2050, from nearly 77 million cases to nearly 74 million cases. In women, OSA may cause fatigue, insomnia symptoms, brain fog, or mood changes—not the typical nighttime snoring and daytime sleepiness.